XML 52 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill and Intangible Assets - General Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Jun. 02, 2016
Dec. 31, 2017
Lesinurad transaction    
Business Combinations    
Payment for acquisition of lesinurad license $ 100,000  
Contingent consideration $ 67,885  
Licensing agreement | AstraZeneca    
Business Combinations    
Royalty percentage per agreement single digits  
Milestone payment to be paid by company upon milestone achievement $ 165,000  
Milestone payment made   $ 15,000
Licensing agreement | Post-marketing Activities    
Business Combinations    
Period for reimbursement amount of development activities (in years) 10 years  
Licensing agreement | Post-marketing Activities | Maximum    
Business Combinations    
Reimbursement obligation $ 100,000